Japan Single-Use Bioprocessing Market 2026 – 2035

The market size of Japan in single-use bioprocessing is estimated to be USD 1.24 Billion in 2025 and is estimated to grow at a CAGR of 16.70% between 2026 and 2035 to USD 1.45 billion and then rise to about USD 5.82 billion in 2026 and 2035 respectively.

The market growth is driven by the rapidly expanding biopharmaceutical industry, rising use of cell and gene therapies, the rising demand of flexible manufacture solutions, the government favoring regenerative medicine, increasing biosimilar productions, the risk of contamination reduction by needs, as well as technologies in disposable bioprocessing systems.

Market Highlight

• Japan is the third largest country market of single-use bioprocessing in the Asia-Pacific region, with a market share of about 8% in 2025.

• According to product type, the single-use bioreactors segment had an approximate market share of 42 in 2025.

• By product type, the segment of filtration assemblies is increasing at the highest CAGR of 18.5% between 2026 and 2035.

• Application The cell culture segment will provide the largest market share of 38% in 2025 and the filtration segment is projected to grow at a CAGR of 17.8% during the foreseen period between 2026 and 2035.

• By workflow, upstream bioprocessing has claimed 61.3% of the market in 2025, with the fastest increase of 18.2% CAGR in downstream bioprocessing.

• In Japan, the biopharmaceutical manufacturing industry employed more than 98,000 full-time workers in 2024, and single use bioprocessing technologies were estimated to support some 22,000 jobs in manufacturing, quality control and technical support functions.

Significant Growth Factors

The Japan Single-Use Bioprocessing Market Trends present significant growth opportunities due to several factors:

• Adoption of Cell and Gene Therapy Manufacturing Platforms:

Cell and gene therapies have been the most rapidly expanding sector in the biopharmaceutical sector in Japan, and the PMDA has approved several new cell therapy products in 2024 and 2025 including autologous CAR-T cell therapies, allogeneic iPS cell-derived products, and gene therapy vectors, which have increased the demand for specialized single-use bioprocessing equipment tailored to the manufacture of personalized medicine.

In August 2025 allogeneic iPS cell-derived dopaminergic neural progenitor cells to treat Parkinson's disease were applied to manufacturing and marketing authorization with S-RACMO as the contract manufacturer through the use of single-use bioprocessing platforms to ensure safety and consistency of their product and reduce the risk of contamination when using autologous cell therapy to produce these products. Complexity of cell and gene therapy production requires closed-system processing where single-use bioreactors, bags, tubing, and connectors supply sterile, validated components that allow aseptic production without having significant cleaning validation requirements as is necessary with more conventional stainless-steel infrastructure. As indicated by industry estimates, more than 70% of the cell therapy production sites in Japan use mostly single-use equipment in upstream cell growth and downstream processing, whereas percentages rise to about 95% in those facilities focused solely on personalized autologous therapies and demand products turn over rapidly and batch processing is done in batches. In 2024, the Japan Agency for Medical Research and Development (AMED) provided a ¥28.5 billion grant to fund the research of regenerative medicine, which subsidizes the financial activities of academic institutions and biotech companies working on developing novel cell and gene therapies using single-use systems based on bioprocessing platforms to manufacture investigational products to support the use of these in clinical trials.

The production of viral vectors as a gene therapy system is growing at a very high rate, and Japanese companies such as Takeda Pharmaceutical, Astellas Pharma and Daiichi Sankyo are investing in adeno-associated virus (AAV) and lentiviral vectors, manufacturing capability using single-use bioreactors with capacities of between 50 to 2000 liters to back clinical and commercial production. In May 2024, Takeda initiated large-scale production of viral vectors in single-use bioreactors in Thermo Fisher’s DynaDrive single-use bioreactors at 50L, 500L, 3,000L, and 5,000L scales with validation that Thermo Fisher products could provide scalable single-use bioreactors to commercial-scale viral vectors production, and that scaling of single-use bioreactors was successfully demonstrated at 50L, 500L, The regulatory reforms, funding of research, and subsidies of Japanese government on regenerative medicine innovation make the country an Asian-Pacific center of advanced therapy production and commercialization, and single-use bioprocessing technologies are key facilitators of quickening the process of laboratory discovery and clinical implementation of new therapeutic approaches.

• Biosimilar Production Expansion and Cost Reduction Imperatives:

The biosimilar market in Japan is growing at a faster rate due to the expiration of patents of the blockbuster biologics, government policies that encourage the use of biosimilars to lower healthcare expenses and also the strategic investments by pharmaceutical companies in the development of biosimilars using cost-effective manufacturing platforms such as the single-use bioprocessing systems.

The Ministry of Health, Labour and Welfare reported that in 2024, biosimilar penetration in Japan was at 28% of eligible biologic prescriptions, an impressive increase on 12% in 2020 and with the government aiming to achieve 60% biosimilar utilization by 2030 that will create substantial demand on the flexible, economical nature of manufacturing infrastructure. Japanese pharmaceutical firms such as Fujifilm Kyowa Kirin Biologics, Teva Pharmaceutical Industries Japan, Sandoz Japan and others are building biosimilar portfolios of high-value reference biologics such as adalimumab, trastuzumab, bevacizumab and rituximab with manufacturing models focused on single-use bioprocessing which facilitates rapid product switchover and reduces capital expenditure as compared to traditional multi-product manufacturing facilities. The single-use bioreactors present significant benefits to biosimilar production, flexibility to take on a variety of products in one plant without extensive cleaning validation, shorter setup times to allow quicker campaign changes, and lower capital costs are especially valuable when large-scale batches are required due to the needs of the Japanese market.

Fujifilm Diosynth Biotechnologies has a flexible production site in Research Triangle Park, North Carolina which serves the biosimilar development programs of Japanese pharmaceutical customers, with 2,000-liter and 20,000-liter single-use bioreactor trains which allow production portfolios based on high-mix low-volume production and high-mix switching products which would otherwise be economically unfeasible with dedicated stainless-steel equipment. Single-use bioprocessing economic benefits are especially appealing to manufacturers of biosimilar, where capital savings of between 40 and 50% when life-cycle capital expenditures are compared to those of a traditional stainless-steel plant can offer faster payback on investment and further support project economics in particular in the biosimilar marketplace that faces competitive prices and is sensitive to operational efficiency. Water and energy savings that come with single-use bioprocessing are aligned with the sustainability goals of Japanese manufacturers, and with the removal of clean-in-place (CIP) and steam-in-place (SIP) needs, the savings in water and energy consumption are about 60-80% and 30-50% respectively at the same time that the wastewater generation and environmental footprint are decreased.

What are the Major Advances Changing the Japan Single-Use Bioprocessing Market Today?

• Large-Scale Single-Use Bioreactor Technology Commercialization:

One of the most dramatic changes in single-use bioreactors has been the shift of single-use bioreactors from experimental devices used in laboratory scale studies to commercial-scale manufacturing platforms, which have become not only as volumetrically productive as traditional stainless-steel production systems but have also retained the flexibility and contamination reduction benefits. The Thermo Fisher Scientific DynaDrive single-use bioreactor platform in 50L, 500L, 2,000L, 3,000L and 5,000L scales is a technological breakthrough that facilitates commercial production of biologics using a disposable bioreactor platform with two 5,000L systems installed at the Yokohama facility in 2026 marking Japan as having entered the field of ultra-large-scale single-use bioreactors.

The 5,000-liter scale is the point of inflection, where the single-use systems have similar or greater economics to stainless-steel alternatives, and Thermo Fisher achieved 27% product and packaging waste reduction compared to 2,000 L legacy systems with 12:1 turndown ratios to provide economic flexibility of working between 400 L and 5,000 L batch sizes. The Sartorius AG Biostat STR Generation 3 platform with scalable volumes of 50 L to 2,000 L with integrated DeltaV automation offers solutions based on validated scalable commercial biologics manufacturing to Japanese manufacturers, with several systems in place at large pharmaceutical companies such as Takeda, Astellas and Daiichi Sankyo supporting the manufacture of monoclonal antibodies and recombinant proteins.

The Xcellerex magnetic mixer was presented in 2,000 L and 3,000 L by Cytiva in 2025 in direct response to the need to solve large scale buffer preparation problems in single-use facilities, in which technology enabled the elimination of the use of impellers, reducing the formation of particulates and enhancing mixing efficiency required in downstream purification processes. By acquiring high-cell-density perfusion culture capabilities in single-use bioreactors, Japanese producers are able to realize productivities of more than 10 grams per liter to rival or better the traditional fed-batch processes at a fraction of the facility footprint and capital costs especially beneficial in the high real-estate-cost Japanese manufacturing environment. Systems with process analytical technology (PAT) integration such as real-time pH, dissolved oxygen, glucose, lactate and cell density sensors allow advanced control of the process in a single-use bioreactor supplied by Sartorius and Cytiva.

• Advanced Filtration and Purification Single-Use Technologies:

The Downstream bioprocessing is a fast developing subsector of the single-use market, with the fastest growing segment of the filtration assemblies segment increasing at 18.5% CAGR due to technological advancements in tangential flow filtration, membrane adsorbers, and chromatography systems that allow full downstream bioprocessing with disposable components. In 2024 Sartorius introduced the Sartobind Rapid A Lab membrane adsorber which is a single-use alternative to packed-bed Protein A chromatography, with technology having similar binding capacity and purity but no sanitization of the resin needed and taking about 40% less processing time especially useful in small-scale antibody purification in research and early clinical manufacture. The concentration and diafiltration process fields in Japanese bio-manufacture are dominated by Tangential flow filtration (TFF) systems with single use cassettes which offer validated, pre-sterilized filtration assemblies capable of supporting clinical and commercial production without membrane integrity tests and cleaning validation considerations as in reusable systems.

The filtration segment is expected to grow at a rate of 17.8% CAGR between 2026 and 2035 due to a rise in monoclonal antibody production, a rise in viral vector production for genetic therapies, and an increase in the use of continuous bioprocessing workflows which need integrated single-use filtration solutions in all workflow steps of the upstream and downstream units. A variety of single-use depth filters and sterile filtration capsules offered by companies such as Pall Corporation, Sartorius and Merck Millipore give Japanese manufacturers full single-use packages of harvest clarification and final product sterilization, and gamma-irradiated pre-assembled units are guaranteed to be sterile without increasing setup time or risking contamination during assembly and integrity testing of filters.

Ready-to-use chromatography columns such as the ReadyToProcess by GE Healthcare and the NGC Chromatography Systems by Bio-Rad are single-use formats of capture, intermediate purification and polishing steps in purifying monoclonal antibodies, and Japanese manufacturers are beginning to adopt these technologies in clinical manufacturing and small scale commercial production where the capital cost and validation of traditional packed columns are more expensive than the economic gains. Continuous introduction of bioprocessing workflows that combine continuous capture chromatography and perfusion bioreactors with inline filtration is an area of emerging application and Japanese research institutions such as Osaka University and Tokyo Institute of Technology are collaborating with equipment vendors in developing single-use platforms that support next-generation intensified bioprocessing.

• Digital Integration and Smart Single-Use Systems:

The integration of single-use bioprocessing with digital technologies such as sensors, automation, data analytics, and artificial intelligence is a transformative development with the ability to provide high-level monitoring, control, and optimization of processes with the flexibility and reduction of contamination risks that are benefits of disposable systems. In April 2025, Sartorius Stedim Biotech collaborated with Tulip Interfaces to launch Biobrain Operate on Tulip, a family of digital manufacturing applications to operate on Sartorius equipment to minimize variability in the processes and digitize operations and regulatory compliance in support of paperless manufacturing and resource efficiency in bioprocessing plants.

Single-use tools such as bioreactor bags, mixing systems, and filtration assemblies can have embedded sensors to perform real-time monitoring of the process without altering sterility or necessitating invasive sampling, with technologies such as non-invasive optical sensors of cell density, metabolite concentration in the product, and titer of the product that can provide the Japanese manufacturers with a comprehensive understanding of the process supporting quality-by-design designs required by PMDA. Single-use components can be RFID tagged to allow automated inventory control and component tracking, as well as assembly verification with minimal human error and better documentation quality to ensure compliance with regulations in the pharmaceutical manufacturing industry, including several Japanese facilities operating RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RFID-enabled single-use RF Artificial intelligence and machine learning systems are being created that can ultimately maximize cell culture conditions by high-throughput metabolite profiling, where AI-based software at Shimadzu Corporation can use mass spectrometry data on cell culture supernatants to suggest feeding strategy, pH adjustments and harvest timing that can enhance productivity and consistency and reduce development time.

Data management platforms based on clouds are secure in storing, sharing and analysing single-use bioprocessing data across multiple facilities and across organisations, Thermo Fisher Scientific, Sartorius and Cytiva, provide digital ecosystems linking equipment, sensors, analytics and enterprise systems to support the transfer of technology, optimization of processes and regulatory compliance. The government of Japan is currently supporting Industry 4.0 and other digital transformation efforts in drug production via METI programs, and this gives a company a reason to invest in smart manufacturing systems, with single-use bioprocessing systems being the best platforms where digital transformation can be implemented due to their modular design and growing sensor compatibility.

Category Wise Insights

By Product Type

Why Single-Use Bioreactors Lead the Market?

The highest segment, single-use bioreactors, will take up about 42% of the total market share in 2025. This leadership indicates the important role of bioreactors as the center of manufacture of biologics and such systems directly influence the productivity, quality of products and flexibility of operations during cell culture processes. The use of single-use bioreactors prevails because of the capability to avoid cross-contamination between batches and products, lower facility cleaning requirements by about 80% in comparison with stainless steel systems, allow product changeover rapidly with set-up times taken in days or weeks, and offer capital cost benefits, especially when it comes to multi-product facilities or new biotech companies.

The segment enjoys the ongoing technological innovation with manufacturers such as Thermo Fisher Scientific, Sartorius, Cytiva, and Eppendorf proving to have larger-scale systems, enhanced mixing and oxygen transfer functions, built-in sensor packages, and automation compatibility to overcome the historical constraints to commercial-scale adoption. An analysis of the new biopharmaceutical manufacturing plants constructed in Japan between 2020 and 2024, per the data of the Japan Pharmaceutical Manufacturers Association, provided evidence of a fundamental change in the approach of replacing single-use bioreactors as the primary cell culture platform in over 65% of new biopharmaceutical manufacturing plants, with the traditional stainless-steel infrastructure giving way to flexible disposable systems.

The most prevalent sub-segment is stirred bioreactors, which occupy about 70% of the single-use bioreactor installations because they are versatile between mammalian and microbial cell culture uses, can scale in size between 50-liter and 5,000-liter working volumes and are similar to traditional stainless-steel stirred reactor processes, allowing the transfer of technology and validation of the process. Wave-induced bioreactors have niche applications in the expansion of seed trains, production of viral vectors, and the production of cell therapies, such as Cytiva's Xcellerex and Sartorius BIOSTAT RM with agitation gentle enough to avoid shear effects on cells yet still having closed-system sterility that is crucial to the production of autologous cell therapies. The installation of two 5,000-liter single-use bioreactors supplied by Thermo Fisher called DynaDrive to be installed at the AGC Biologics Yokohama facility planned to be operational in 2026 is being considered as a landmark development, indicating the commercial viability of large-scale single use systems to produce blockbuster antibodies, operation in perfusion mode and high cell densities in 5,000-liter Systems.

The most rapidly growing assemblies are filtration assemblies with a projected CAGR of 18.5% growth between 2026 and 2035 due to the growing use of downstream bioprocessing, growth in the use of continuous manufacturing workflow that requires integrated filtration in all unit operations and technological advancement in membrane adsorbers and chromatography systems that allow trains of purification to be completely disposable. The segment has the advantage of tangential flow filtration prevailing in concentration and diafiltration systems, with Japanese producers undertaking thousands of TFF operations each year in antibody purification, viral vector concentration, and protein formulation using Sartorius, Merck Millipore, and Pall single-use cassettes. It is less time consuming and has better product recovery than traditional centrifugation systems. Single-use bind-and-elute and flow-through purification systems such as membrane adsorbers such as Sartobind (Sartorius) and Mustang (Pall), have technologies with fast processing speeds and low buffer use and remove the need to pack and sanitize resin as well as lifetime validation, which is especially beneficial to clinical manufacturing and small-scale commercial purification. The increasing viral vector production industry that arises due to the progress of gene therapies demands large quantities of customised filtration assemblies with production protocols necessitating numerous steps of clarification, concentration and buffer change during downstream processing which is dominated by single-use technologies.

By Application

Why Cell Culture Dominates Single-Use Bioprocessing Applications?

The biggest segment is cell culture applications which supply about 38% of total market share in 2025. This leadership is based on the primal role of cell culture as the core of manufacturing recombinant proteins, monoclonal antibodies, vaccines, and cell therapies, where the results of the production process directly depend on the performance of bioreactors, management of media, and environmental regulation that demand advanced single-use systems. Cell culture is the most active and critical area of application in biopharmaceutical manufacturing, with Japanese firms generating more than 2.8 trillion yearly in biologics using mammalian and microbial cell culture platforms, of which Chinese hamster ovary (CHO) cells are used to express nearly 70% of therapeutic proteins, and Escherichia coli is the primary expression system to produce biosimilar insulin as well as growth hormones and other relatively simple protein therapeutics. Single-use bioreactors are ideal to use in cell culture applications, as they have precise control of temperature, pH, dissolved oxygen and agitation to maintain the cells in optimal growth conditions with advanced bioreactors with integrated sensors and automated feeding strategies that optimize their productivity.

The segment enjoys surging production of complex biologics such as bispecific antibodies, antibody-drug conjugates and fusion proteins that require special cell culture conditions, media formulations and harvesting plans in single facilities that do not become cross-contaminated. Viral vector production as a sub-market in gene therapy applications is in the form of adeno-associated virus (AAV) manufacturing, which uses purpose-built single-use bioreactor platforms such as the iCELLis of Pall and the DASbox of Eppendorf designed to support adherent cell culture as a basis of high-titer vector production needed in clinical and commercial gene therapy manufacturing. Production of cell therapy is mostly based on single-use culture vessels such as CellSTACK, HYPERStack and Ascent Fixed Bed Reactor systems that offer closed-system cell expansion in both autologous and allogeneic therapies with systems as small as research flasks to large-scale commercial production platforms capable of supporting billions of cells per run in CAR-T and other cellular immunotherapy applications.

The fastest growing filtration with the projected CAGR of 17.8% between 2026 and 2035 is due to the growing need to clarify high-density cell cultures, rising demand of virus filtration due to the need to ensure products are safe, and increased need to adopt continuous bioprocessing that demands inline filtration during manufacturing processes. The filtration application market has the advantage of universal use in all biologics manufacturing processes, as all monoclonal antibodies, recombinant proteins, vaccines, and gene therapies require multiple filtration processes such as harvest clarification (cell and debris removal), virus filtration (viral safety assurance), and sterile filtration (final product sterility aseptic filling procedures). Tangential flow filtration is predominant in concentration and buffer exchange applications and Japanese manufacturers carry out over 15,000 TFF operations each year using single-use systems with the technology having a better product recovery, faster run time and greater consistency than traditional batch ultrafiltration and diafiltration processes. Harvest Clarification Depth filtration is a significant use, single-use capsules such as the SUPRAcap of Pall and Millistak of Merck allow the rapid removal of cells, cell debris and colloidal substances generated during a bioreactor harvest with minimal product loss and less processing time than centrifugation-based clarification. Virus filtration to assure the safety of products is a key downstream application whose single-use virus filters like the Viresolve and Pegasus systems of Merck and Pall respectively have been validated to provide viral clearance of monoclonal antibodies and recombinant proteins to regulatory standards at a significantly lower cost than reusable systems (filter integrity testing and validation).

By Workflow

Why Upstream Bioprocessing Dominates the Market?

Upstream bioprocessing constitutes the biggest portion that will have about 61.3% of the market share in 2025. This dominance is an indicator of the capital intensity in upstream operations based on the fact that bioreactors, media preparation systems and seed train equipment constitute the majority of the single use product consumption and that the performance of the upstream process directly dictates the overall manufacturing productivity and product quality. Upstream bioprocessing includes all processes between cell banking and final harvest including inoculum preparation, seed train expansion, production bioreactor culture and harvest operations with single-use technologies, which have significant benefits across the workflow, such as lower risk of contamination, faster batch turnaround and higher operational flexibility.

The segment has the advantage of high adoption of bioreactors, with systems sizes of 50-liter to 5,000-liter volumes using massive volumes of single use bags, sensors, tubing and connectors per batch, with Japanese plants having hundreds of upstream production campaigns each year, which are served by the CDMO business. The most common product consumption category in the upstream workflow is the media bags and containers, whose batch size is 500-liter and 20,000 liters and which need the special bag design with 2D and 3D to be stored, thawed, and transferred, and Sartorius, Thermo Fisher, and Merck offer ready to use, validated containers, saving time in preparation and guaranteeing the quality of media.

The use of single use shake flasks, spinner flasks and small scale bioreactors is becoming common to carry out seed train operations that grow cells using working cell banks up to production scale inoculum, with closed system transfers in between vessels limiting the risk of contamination but also reducing the facility classification requirements as well as the construction and operating costs of such facilities. Perfusion culture is a growing upstream application, where continuous cell culture systems reach cell densities of more than 100 million cells per milliliter and productivities of more than 20 grams per liter, and technologies such as alternating tangential flow filtration (ATF) and acoustic wave separation allow cell retention and the removal of spent media and product making opportunities for intensified bioprocessing in a smaller facility.

By End User

Why Biopharmaceutical Manufacturers Lead End-User Adoption?

The biggest end-user market is the biopharmaceutical manufacturers, who constitute nearly half of the market share in 2025. This dominance is shown through the large investment of the pharmaceutical industry in the production infrastructure of biologics, with major Japanese companies, such as Takeda Pharmaceutical, Daiichi Sankyo, Astellas Pharma, Chugai Pharmaceutical, and Eisai having dedicated biologics manufacturing plants utilizing monoclonal antibody, recombinant protein and vaccine manufacturing using single use bioprocessing systems to support domestic and international markets.

The single-use technologies of these manufacturers are advantageous due to the flexibility to manufacture many products in one facility, and they have a high rate of changing products quickly, which is highly useful during the seasons when they need to produce the vaccines and produce therapeutic proteins all year round without the need to use large-scale cleaning validation and potential contamination of the equipment of the old models due to shared use. Domination of the segment is further enhanced by the rise in production of biosimilars, with Japanese manufacturers such as Fujifilm Kyowa Kirin Biologics among others developing portfolios of biosimilar antibodies and proteins using cost-effective single-use platforms that provide capital expenditure savings and operational flexibility, which are key to competitive biosimilar economics. Manufacturers of regenerative medicine products capture the fast-growing sub-segment, where autologous and allogeneic cell therapies are manufactured, and the manufacturers use single use bioprocessing equipment because of the patient specific manufacturing needs, reduction of contamination risks and regulatory biases towards closed-system processing as a means of providing product safety and consistency.

The largest growth is anticipated in the Contract Development and Manufacturing Organizations (CDMOs) with a CAGR of 19.5% between 2026 and 2035 due to the rising activities of outsourcing biologics production to biotech firms, the focus on core competencies in the pharmaceutical industry and the expansion of capacity in the CDMOs by government subsidies and client demand to outsource flexible manufacturing services.

The Japanese CDMOs such as AGC Biologics, Fujifilm Diosynth Biotechnologies, JCR Pharmaceuticals and S-RACMO are increasing their single-use production capacities to satisfy various client company needs with AGC Biologics 5,000-liter bioreactor carrier and S-RACMO's 15-billion CRAFT facility being good capacity additions that make Japan the biologics manufacturing centre in Asia-Pacific. Single-use technologies are also disproportionately helpful to CDMOs because of the multi-product nature of their business, with a typical CDMO facility being able to support 10-30 client products a year with products requiring rapid changeovers, which would have been economically out of reach with traditional stainless-steel infrastructure where deep cleaning validation between campaigns is required. Cell and gene therapy production demand further boosts the growth of the CDMO segment with more than three-quarters of the cell therapy developers outsourcing their manufacturing capabilities to specialized CDMOs equipped with expertise, infrastructure, and regulatory compliance capabilities to support the manufacture of complex modalities, including autologous CAR-T therapies and allogeneic iPS cell products.

Report Scope

Economic Impact Analysis

How Significant is the Industry's Economic Contribution?

The Japanese biopharmaceutical manufacturing industry, to which single-use bioprocessing is an important part that is gaining more and more critical, makes a significant contribution to the national economic output both in direct manufacturing operations, research and development, job creation, and supporting healthcare facilities. The biopharmaceutical manufacturing industry made about ¥7.2 trillion in production value in 2024 with single-use bioprocessing technologies, which support about 35% of the production output, or ¥2.5 trillion in economic value through flexible manufacturing platforms supporting a wide array of product portfolios. In 2024, the industry had direct employment exceeding 98,000 people working in manufacturing, quality control, regulatory affairs and technical support positions of single-use bioprocessing technologies, and the average annual pay of disposable systems operating, supply chain management and process development functions was more than ¥6.8 million, which is highly skilled in nature.

The employment multiplier effect spreads across the entire supply chain with the single-use component manufacturers, sterilization service providers, logistics companies, and waste management firms generating an estimated 48,000 other jobs in support of the single-use bioprocessing ecosystem of the Japanese industrial economy. Cumulative research and development spending on biopharmaceutical production technologies reached ¥95 billion in 2024, pharmaceutical companies, equipment manufacturers, and government research establishments were developing next-generation single-use systems, advanced sensors, automation platforms, and process analytical technologies, which made Japan world competitive in biologics production. The Contract Development and Manufacturing Organization (CDMO) market is undergoing significant growth, with Japanese CDMOs such as AGC Biologics, Fujifilm Diosynth Biotechnologies, JCR Pharmaceuticals, and S-RACMO earning the nation over 180 billion yen in 2024 supplying local biotech firms and foreign pharmaceutical companies with the need to have flexibility in their manufacturing capacity through the use of mostly single-use bioprocessing platforms.

What is the Industry's Innovation and Infrastructure Impact?

Japan has good standing in innovation in bioprocessing with domestic equipment players such as Asahi Kasei, SATAKE MultiMix, and ZACROS producing special purpose single-use parts, and international players like Thermo Fisher Scientific, Sartorius and Cytiva having a presence in Japan, offering local technical support, training, and application development services. In July 2025, the Ministry of Economy, Trade and Industry introduced the Regenerative Medicine CDMO Subsidy Program, giving large amounts of government funding to upgrades of facilities and equipment installation in the fields of regenerative medicine, cell therapy, and gene therapy production, and several companies have been granted subsidies up to 50% of capital spending on high-performance single-use bioprocessing platforms.

The 15 billion invested in the third regenerative medicine production facility CRAFT in S-RACMO, which is scheduled to be fully completed in August 2025, and the fourth planned facility, indicates that the private sector believes in the future of biomanufacturing in Japan and that the central role in the production of its autologous and allogeneic cell therapies lies in single-use technologies. AGC Biologics' intentions to install two 5,000-liter single use bioreactors at its Yokohama plant, the DynaDrive, are a potential ¥8 billion investment that will be operational in 2026, the first investment in ultra-large-scale commercial single-use manufacturing to serve both domestic and international customers requiring high-volume antibody manufacturing. Combining Industry 4.0 technology sensors, automation, data analytics, and artificial intelligence with single-use bioprocessing platforms, Japanese manufacturers are on the leading edge of smart manufacturing, and Sartorius Biobrain Operate digital manufacturing applications and other platforms allow paperless operations, real-time process monitoring, and predictive analytics to increase productivity, as well as guarantee regulatory compliance. The collaboration between major universities such as the University of Tokyo, Kyoto University, and Osaka University and equipment manufacturers and Pharmaceutical Companies developing new bioprocessing technologies can lead to successful academic-industry collaboration with government research funding provided by AMED, MEXT, and JST that facilitates the translation of the laboratory discovery into the manufacturing platform.

Top Players in the Market

• Thermo Fisher Scientific Japan

• Sartorius Japan

• Merck KGaA (Japan operations)

• Cytiva (Danaher Japan)

• Eppendorf Japan

• Asahi Kasei Corporation

• SATAKE MultiMix Corporation

• Pall Corporation (Japan)

• Repligen Corporation (Japan)

• ZACROS Co. Ltd.

• Boehringer Ingelheim Japan

• REPROCELL Inc.

• Others

Key Developments

The market has undergone significant developments as industry participants seek to expand capabilities and enhance product portfolios.

• In August 2025: S-RACMO finished its third regenerative medicine production plant, CRAFT (Center for Regenerative Medicine and Future Therapy), with an investment of about 15 billion to increase production capacity and the fourth facility is planned, which forms a complete single-use bioprocessing infrastructure to produce autologous and allogeneic cell therapies through clinical trials and commercial production.

• In July 2025: The Ministry of Economy, Trade and Industry introduced the Regenerative Medicine CDMO Subsidy Program, subsidizing facility upgrades and equipment installations used to support regenerative medicine manufacturing by a maximum of 50%, with JCR Pharmaceuticals, S-RACMO and other major companies getting significant government funding to jumpstart the use of single-use bioprocessing.

• In April 2025: Sartorius Stedim Biotech partnered with Tulip Interfaces to introduce Biobrain Operate on Tulip, which operates on Sartorius equipment; a suite of digital manufacturing applications to decrease variability in processes, digitalize operations, and ensure regulatory compliance to help paperless manufacturing at single-use bioprocessing plants.

• In April 2025: AGC Biologics stated that it would install two 5,000 liter DynaDrive single-use bioreactors from Thermo Fisher scientific at its Yokohama facility that will commence operations in 2026, the largest commercial-scale single-use bioprocessing installation in Japan, supporting production of high-volume monoclonal antibodies by global pharmaceutical firms.

These strategic activities have allowed companies to strengthen market positions, expand manufacturing capabilities, enhance technological infrastructure, and capitalize on growth opportunities within the expanding market.

The Japan Single-Use Bioprocessing Market is segmented as follows:

By Product Type

• Single-Use Bioreactors (SUBs)

o   Stirred-Tank Bioreactors

o   Wave-Induced Bioreactors

o   Bubble Column Bioreactors

o   Others

• Media Bags and Containers

o   2D Bags

o   3D Bags

o   Bioprocess Containers

o   Others

• Filtration Assemblies

o   Tangential Flow Filtration (TFF)

o   Depth Filters

o   Sterile Filtration Capsules

o   Membrane Adsorbers

• Disposable Mixers

o   Magnetic Mixers

o   Rocking Platform Mixers

o   Others

• Tubing and Connectors

o   Transfer Tubing

o   Aseptic Connectors

o   Sample Bags

• Other Products

o   Sampling Systems

o   Sensors

o   Accessories

By Application

• Cell Culture

• Filtration

• Purification

• Storage

• Mixing

• Other Applications

By Workflow

• Upstream Bioprocessing

• Downstream Bioprocessing

• Process Development

By End User

• Biopharmaceutical Manufacturers

• Contract Development and Manufacturing Organizations (CDMOs)

• Academic and Research Institutions

• Other End Users

By Type of Cell

• Mammalian Cells

• Microbial Cells

• Other Cell Types